Acorda Therapeutics, Inc. (ACOR)
| Market Cap | 18.08M |
| Revenue (ttm) | 111.12M |
| Net Income (ttm) | -15.95M |
| Shares Out | 1.20M |
| EPS (ttm) | -1.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,598 |
| Open | 14.70 |
| Previous Close | 14.99 |
| Day's Range | 14.14 - 15.09 |
| 52-Week Range | 9.00 - 24.20 |
| Beta | 1.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2023 |
About ACOR
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member ... [Read more]
Full Company ProfileFinancial Performance
In 2022, ACOR's revenue was $118.57 million, a decrease of -8.14% compared to the previous year's $129.07 million. Losses were -$65.92 million, -36.59% less than in 2021.
Financial StatementsNews
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Third Quarter 2023 Financial Results.
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023.
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®.
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2023 Financial Results.
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The FightersTM”.
Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023.
Tom Burns Elected to the Acorda Therapeutics Board of Directors
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Tom Burns Elected to the Acorda Therapeutics Board of Directors.
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement.
Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement.
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split.
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split.
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A.
Acorda Therapeutics Reports First Quarter 2023 Financial Results
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports First Quarter 2023 Financial Results.
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash.
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China.
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023.
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting.
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2022.
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
PEARL RIVER, N.Y.
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
PEARL RIVER, N.Y.
Acorda Therapeutics to Present at Sequire Biotechnology Conference
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer, will make a virtual presentation at the S...
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that on December 31, 2022 it entered into a new long-term global supply agreement with Catalent for the m...
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has revised and updated the long-term financial guidance most recently included in its November 1...
Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that, due to the ...
Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it made a cash interest payment of approximately $6.2 million due on December 1, 2022 under its Conv...